Clinical Trial Update: Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence [Phase 1]

View source ↗

Summary

Phase 1 study evaluating bevacizumab delivered into the tumor resection cavity for glioblastoma at first recurrence has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Avastin (bevacizumab)

Snippet

Sponsor: Brain & Spine Surgeons of New York | Conditions: Glioblastoma Multiforme | Phase 1 | Status: TERMINATED